Tildacerfont
Small moleculeexperimental
Clinical trial activity
6 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
6
Phase 3
0
Phase 4
0
Earliest trial started Jul 26, 2017 (NCT03257462)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
BAZ1A antagonist
Chemistry & pharmacology
Loading structure…
SMILES
CCC(CC)c1cc(C)nc2c(-c3nc(N4CCOCC4)sc3Cl)c(C)nn12- Mol. weight
- 419.98 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095198 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05370521 | Phase 2 | May 15, 2022 | Spruce Biosciences |
| NCT05128942 | Phase 2 | Dec 31, 2021 | Spruce Biosciences |
| NCT04544410 | Phase 2 | Sep 29, 2020 | Spruce Biosciences, University of California, San Diego |
| NCT04457336 | Phase 2 | Aug 26, 2020 | Spruce Biosciences, University of Minnesota |
| NCT03687242 | Phase 2 | Sep 6, 2018 | Spruce Biosciences |
| NCT03257462 | Phase 2 | Jul 26, 2017 | Spruce Biosciences, University of Michigan |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Spruce Biosciences | For profit | 6 | 6 | 1 | 2017 |
| University of California, San Diego | Academic/Hospital | 1 | 0 | 1 | 2020 |
| University of Michigan | Academic/Hospital | 1 | 0 | 1 | 2017 |
| University of Minnesota | Academic/Hospital | 1 | 0 | 1 | 2020 |
4 organizations
Page 1 / 1